ArticleBlood advances2023

SECTM1-based CAR T cells enriched with CD7-low/negative subsets exhibit efficacy in CD7-positive malignancies.

Wenwen Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.